NEW BRUNSWICK, N.J., March 13, 2020 – Johnson & Johnson right now introduced that its Janssen Pharmaceutical Corporations have entered a collaboration with the Beth Israel Deaconess Medical Heart (BIDMC) to help the event of a preventive vaccine candidate for COVID-19. The events have commenced preclinical testing of a number of vaccine prospects, with the goal to establish by the tip of the month a COVID-19 vaccine candidate for scientific trials.
Janssen is optimistic that, in collaboration with a number of world strategic companions, it will probably provoke a Section 1 scientific research of a possible vaccine candidate by the tip of the yr. In parallel to those efforts, Janssen is making ready to upscale manufacturing and manufacturing capacities to ranges required to fulfill world public well being vaccination wants.
“It’s vital to work with one of the best scientific minds as we glance to quickly establish and develop options to the COVID-19 outbreak,” stated Paul Stoffels, M.D., Vice Chairman of the Govt Committee and Chief Scientific Officer, Johnson & Johnson. “We’re grateful for proficient and skilled collaboration companions like Dan Barouch and his workforce at BIDMC. By mobilizing our collective assets, we imagine we will leverage the highest science and cutting-edge capabilities to reply to this pandemic.”
Janssen’s vaccine program will use the Janssen AdVac® and PER.C6® applied sciences that present the power to quickly upscale manufacturing of an optimum vaccine candidate. The corporate is leveraging its confirmed vaccine know-how that it is usually utilizing to develop its investigational Ebola (which additionally makes use of its MVA-BN® know-how), Zika, RSV and HIV vaccines. Analysis and collaboration on preclinical work for our Zika and HIV vaccine candidates on the Heart for Virology and Vaccine Analysis at Beth Israel Deaconess Medical Heart was foundational to creating these vaccines.
Dan Barouch, M.D., Ph.D., Director of the Heart for Virology and Vaccine Analysis at BIDMC and the Ragon Institute, said, “We’re presently evaluating a collection of potential vaccine candidates for COVID-19. This collaboration with Janssen is aimed on the improvement of a COVID-19 vaccine that will permit for fast improvement, large-scale manufacturing, and world supply.”
Dr. Barouch’s workforce is well-known for his or her work on the pathogenesis and immunology of viral infections and the event of vaccine methods for world infectious ailments.
Johnson & Johnson’s efforts to expedite improvement and manufacturing of a vaccine are enhanced by the prevailing COVID-19 vaccine collaborations between Janssen and the Biomedical Superior Analysis and Growth Authority (BARDA), a part of the Workplace of the Assistant Secretary for Preparedness and Response (ASPR) on the U.S. Division of Well being & Human Providers.
Along with Janssen’s efforts to develop a vaccine candidate, the Firm is working carefully with world strategic companions to display screen its library of antiviral molecules to speed up the invention of potential COVID-19 therapies and supply reduction for individuals around the globe.
For extra info on Johnson & Johnson’s multipronged response to figuring out vital options to the COVID-19 outbreak, please go to:
About Johnson & Johnson
At Johnson & Johnson, we imagine good well being is the muse of vibrant lives, thriving communities and ahead progress. That’s why for greater than 130 years, now we have aimed to maintain individuals effectively at all ages and each stage of life. At the moment, because the world’s largest and most broadly-based healthcare firm, we’re dedicated to utilizing our attain and dimension for good. We attempt to enhance entry and affordability, create more healthy communities, and put a wholesome thoughts, physique and atmosphere inside attain of everybody, all over the place. We’re mixing our coronary heart, science and ingenuity to profoundly change the trajectory of well being for humanity. Be taught extra at Comply with us at @JNJNews.
In regards to the Janssen Pharmaceutical Corporations
At Janssen, we’re making a future the place illness is a factor of the previous. We are the Pharmaceutical Corporations of Johnson & Johnson, working tirelessly to make that future a actuality for sufferers all over the place by preventing illness with science, enhancing entry with ingenuity, and therapeutic hopelessness with coronary heart. We give attention to areas of medication the place we will make the largest distinction: Cardiovascular & Metabolism, Immunology, Infectious Illnesses & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Be taught extra at Comply with us at @JanssenGlobal.
Discover to Traders Regarding Ahead-Trying Statements
This press launch comprises “forward-looking statements” as outlined within the Non-public Securities Litigation Reform Act of 1995 concerning darunavir/cobicistat and improvement of potential preventive and remedy regimens for COVID-19. The reader is cautioned to not depend on these forward-looking statements. These statements are primarily based on present expectations of future occasions. If underlying assumptions show inaccurate or identified or unknown dangers or uncertainties materialize, precise outcomes may differ materially from the expectations and projections of the Janssen Pharmaceutical Corporations and/or Johnson & Johnson. Dangers and uncertainties embrace, however should not restricted to: challenges and uncertainties inherent in product analysis and improvement, together with the uncertainty of scientific success and of acquiring regulatory approvals; uncertainty of economic success; manufacturing difficulties and delays; competitors, together with technological advances, new merchandise and patents attained by rivals; challenges to patents; product efficacy or security issues leading to product remembers or regulatory motion; modifications in habits and spending patterns of purchasers of well being care services; modifications to relevant legal guidelines and laws, together with world well being care reforms; and traits towards well being care value containment. An extra record and descriptions of those dangers, uncertainties and different components could be present in Johnson & Johnson’s Annual Report on Kind 10-Okay for the fiscal yr ended December 29, 2019, together with within the sections captioned “Cautionary Observe Relating to Ahead-Trying Statements” and “Merchandise 1A. Threat Components,” and within the firm’s most not too long ago filed Quarterly Report on Kind 10-Q, and the corporate’s subsequent filings with the Securities and Alternate Fee. Copies of those filings can be found on-line at , or on request from Johnson & Johnson. Not one of the Janssen Pharmaceutical Corporations nor Johnson & Johnson undertakes to replace any forward-looking assertion because of new info or future occasions or developments.
Supply: Johnson & Johnson
Posted: March 2020